AgeX Therapeutics, Inc. (AGE): Price and Financial Metrics
AGE Price/Volume Stats
Current price | $11.10 | 52-week high | $35.71 |
Prev. close | $12.60 | 52-week low | $11.07 |
Day low | $11.10 | Volume | 3,700 |
Day high | $12.59 | Avg. volume | 3,849 |
50-day MA | $14.16 | Dividend yield | N/A |
200-day MA | $20.41 | Market Cap | 11.97M |
AGE Stock Price Chart Interactive Chart >
AGE Stock Summary
- AGE's price/sales ratio is 153.42; that's higher than the P/S ratio of 98.13% of US stocks.
- With a year-over-year growth in debt of -85.82%, AGEX THERAPEUTICS INC's debt growth rate surpasses merely 1.71% of about US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for AGE comes in at -117.88% -- higher than that of just 3.75% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to AGEX THERAPEUTICS INC are OPTN, OEC, OI, TTI, and THMO.
- AGE's SEC filings can be seen here. And to visit AGEX THERAPEUTICS INC's official web site, go to www.agexinc.com.
AGE Valuation Summary
- AGE's EV/EBIT ratio is -2; this is 113.7% lower than that of the median Healthcare stock.
- Over the past 62 months, AGE's EV/EBIT ratio has gone up 11.4.
Below are key valuation metrics over time for AGE.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
AGE | 2023-12-29 | 155.3 | -0.5 | -1.0 | -2.0 |
AGE | 2023-12-28 | 157.4 | -0.5 | -1.1 | -2.0 |
AGE | 2023-12-27 | 166.0 | -0.6 | -1.1 | -2.1 |
AGE | 2023-12-26 | 158.5 | -0.5 | -1.1 | -2.1 |
AGE | 2023-12-22 | 155.3 | -0.5 | -1.0 | -2.0 |
AGE | 2023-12-21 | 150.0 | -0.5 | -1.0 | -2.0 |
AgeX Therapeutics, Inc. (AGE) Company Bio
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.
Latest AGE News From Around the Web
Below are the latest news stories about AGEX THERAPEUTICS INC that investors may wish to consider to help them evaluate AGE as an investment opportunity.
Serina Therapeutics Announces POZ Polymer Technology License Agreement with PfizerProvides access to Serina POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company focused on developing its proprietary POZ Platform TM drug delivery technology, including POZ lipid nanoparticle (LNP) delivery systems for RNA-based therapeutics, today announced Serina has entered into a License Agreement under which Pfizer Inc. wil |
AgeX Therapeutics Reports Third Quarter 2023 Financial ResultsALAMEDA, Calif., November 14, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023. |
Serina Therapeutics and AgeX Therapeutics Enter into Merger AgreementHUNTSVILLE, Ala. & ALAMEDA, Calif., August 30, 2023--Serina Therapeutics, Inc. ("Serina"), a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson’s Disease and other neurological diseases, entered into a merger agreement with AgeX Therapeutics, Inc. (NYSE American: AGE) ("AgeX") on August 29, 2023, under which Serina will merge with a wholly-owned subsidiary of AgeX in an all-stock transaction. The combined company will continue u |
AgeX Therapeutics Reports Second Quarter 2023 Financial ResultsALAMEDA, Calif., August 14, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30, 2023. |
AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred StockALAMEDA, Calif., July 24, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 24, 2023, AgeX issued to Juvenescence Limited 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness consisting of the outstanding principal amount of certain loa |
AGE Price Returns
1-mo | -16.23% |
3-mo | -19.27% |
6-mo | -54.29% |
1-year | -52.98% |
3-year | -80.93% |
5-year | -92.33% |
YTD | -19.27% |
2023 | -30.24% |
2022 | -49.37% |
2021 | -28.29% |
2020 | -16.48% |
2019 | -39.13% |
Loading social stream, please wait...